<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1ACF2D37-682E-48E9-8C39-AECA9C57614F"><gtr:id>1ACF2D37-682E-48E9-8C39-AECA9C57614F</gtr:id><gtr:name>Immunocore Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1ACF2D37-682E-48E9-8C39-AECA9C57614F"><gtr:id>1ACF2D37-682E-48E9-8C39-AECA9C57614F</gtr:id><gtr:name>Immunocore Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9E8032DA-7884-4F5A-BC68-F48C4FCFA465"><gtr:id>9E8032DA-7884-4F5A-BC68-F48C4FCFA465</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:surname>Gormley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D33C797B-712D-4BDA-841C-D0E6AFE36362"><gtr:id>D33C797B-712D-4BDA-841C-D0E6AFE36362</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Scott</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001805"><gtr:id>3651BCDA-C640-4AD7-AFA2-E0789D940E64</gtr:id><gtr:title>Evaluation of antibody targeted controlled release nanoparticle systems</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1001805</gtr:grantReference><gtr:abstractText>The overarching objective of this proposal is the pilot evaluation of a novel antibody-drug
delivery technology, developed by the academic partner (Bioconjug Chem. 2008:19(8):1561-
9; Pharm Res. 2008:25(1):135-46), using novel therapeutic antibodies that have been
developed by the industrial partner. Pursuance of this objective will provide the following:
1. Development of the Research Fellow?s research expertise, management and leadership
2. Development of new patent applications around the data produced
3. Technical and commercial evaluation of a new therapeutic approach by the partners
4. Development of a portfolio of data to facilitate future project grant application funding to
agencies such as the MRC
This project builds on the established links between the industrial and academic partners.
These groups have successfully collaborated in the past, producing joint IP, publications in
quality journals (Clinical Cancer Research, Bioconjugate Chemistry and PlosONE), and
ultimately creating jobs and wealth in the local economy. A previous collaboration, focussed
on the transfer of a protein engineering technology from the School of Pharmacy (through a
KTP scheme; awarded A in final report; regional winner 2008), led to the development of a
new bovine TB diagnostic kit by the company, which is currently undergoing evaluation in the
UK and Ireland.
In this current project, the academic partner has developed a novel nanoparticulate drug
delivery system and has already been provided with commercially insensitive antibodies to
test as a proof of principle in vitro by the industrial partner. This project will build on this
base, examining commercially prioritised antibodies (produced using the platform
technologies underpinning the company) in relevant in vivo primary and metastatic tumour
models
We believe that this programme is an ideal mechanism to fund this pilot project, as it not only
provides the scope to undertake the project, but allows the Fellow to learn and champion the
technology, thus developing their own CV, and provides a framework for further funding
opportunities from the MRC such as the DPFS</gtr:abstractText><gtr:technicalSummary>This exchange programme will focus on the development of the Fellow?s expertise in

the development and evaluation of nanoparticulate systems as anti-cancer

therapeutics. This project will not only provide the fellow with various aspects of

research leadership training, but also facilitate the development of a new research

collaboration between the academic and industrial partners; bringing together their

respective skills in nanoparticulate drug systems and therapeutic antibody

development in a pilot study to examine their application using in vivo tumour

models.

This project will bring together the independent research strengths of both

partners, and provide the necessary funding to pursue the evaluation of antibodydirected

nanoparticulate conjugates as anti-cancer drugs, both in terms of

therapeutic effect and toxicity. For the academic partner, this represents a valuable

opportunity to develop a new therapeutic strategy with an industrial partner, who is

focussed on antibody therapeutics. The industrial partner has developed a portfolio

of antibodies towards targets up-regulated on the surface of tumour cells post front

line chemotherapy treatment, and is keen to examine their application in these

nanoparticulate systems ? in both a therapeutic and drug delivery vector capacity.

The academic and industrial partners have collaborated previously, and technology

transfer have been previously undertaken through the Knowledge Transfer

Partnership (KTP). These previous projects have had success outcomes, including

the co-development of a novel antibody therapeutic (Fsn0503) which is now poised

to undergo phase 1 clinical trials. This new project builds on these previous

successful relationships which will form a solid basis in terms of working practises,

route to IP establishment and licensing as required.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-20</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-02-21</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>45444</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunocore Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Immunocore</gtr:description><gtr:id>19FBEC9C-8FB2-49FF-A1A0-57466FE847DF</gtr:id><gtr:impact>This is a multi-disciplinary project bringing together expertise in immunotherapy and drug formulation.

No outputs to report at this time</gtr:impact><gtr:outcomeId>5459025cebe235.46528583-1</gtr:outcomeId><gtr:partnerContribution>Expertise and knowhow in nanotechnology</gtr:partnerContribution><gtr:piContribution>On the basis of previous work that we have undertaken as part of our MRC funded projects, we have been able now to secure a MRC CASE studentship with this SME to evaluate their targeting technologies with our nanotechnologies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation at Belfast Philosophical Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D40C790-0398-45D2-9F37-8449DC42A19E</gtr:id><gtr:impact>Talked to general public about our work in pancreatic cancer, leading to new debate and interest in the research at QUB</gtr:impact><gtr:outcomeId>58c2814695e9b8.28311397</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Debating Matters, Northern Ireland</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A4C79F49-76CE-4DDC-B00E-000FE5715B7E</gtr:id><gtr:impact>Acted as judge for the session of three schhools - approx 20 pupils and teachers

Have been asked to take part in a RCUK-led schools teacher training event</gtr:impact><gtr:outcomeId>k3BFYPZ4dH8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.debatingmatters.com/events/qr/northern_ireland_south_2013_14/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Open Week presentations</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7DBC8F76-27A3-4BBE-963F-F183F612D342</gtr:id><gtr:impact>Demonstrating to the audience the critical need for drug formulation in the development of more effective cancer medicines</gtr:impact><gtr:outcomeId>58c280d5a5cb25.48992612</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit, Armagh</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>74AF7C7F-953B-40A1-A252-E9CB55B24EF4</gtr:id><gtr:impact>30 pupils (6th formers) attended hte workshop to discuss what ressearch is undertaken in school of pharmacy, QUB and what different career aspirations one can have if they do pharmacy at univeristy beyond practising professionally as clinical or community pharmacists

Larger intake of students from that school for the degree</gtr:impact><gtr:outcomeId>oM81mrm6NS2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>15D026B7-DFD6-49F2-8968-B1A38765116A</gtr:id><gtr:impact>30 puils who are interested in undertaking careers with biology background in a career session

invited to take part in session again</gtr:impact><gtr:outcomeId>cAcqmw5gQGD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>88000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>na</gtr:fundingRef><gtr:id>8463E55C-64AF-401B-AD91-6F8D29C940C4</gtr:id><gtr:outcomeId>T6jKGQqwwrw</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>128000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Invest Northern Ireland</gtr:fundingOrg><gtr:fundingRef>poc338</gtr:fundingRef><gtr:id>1037B4F1-2F4C-4E14-A7AE-E62C16B9D78B</gtr:id><gtr:outcomeId>DPtqcEvfc5T</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Trustee of the new British Society of Nanomedicine</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F8221F1-4CF0-4023-8B55-EBCCDF383559</gtr:id><gtr:impact>The mission of the British Society of Nanomedicine to to educate scientists and general public on the role of nano medicine in health and to remove some of the misconceptions that arise in public perception. The Society represents the national body of nano medicine in the UK, is associated with its European partners to strive in the improvement of health using nanotechnology</gtr:impact><gtr:outcomeId>58c28a75406d03.32851756</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.britishsocietynanomedicine.org</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This new PEGylated polymer has been developed in house that facilitates the surface attachment of antibodies onto particles for in vivo experiments</gtr:description><gtr:id>2668C44F-04E3-435F-AC27-049FD91AF955</gtr:id><gtr:impact>This polymer will allow us to analyse the ability of antibodies to not only target tumours in vivo, but also elicit receptor activation</gtr:impact><gtr:outcomeId>NPTvHnWLgEr</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>new PEGylated polymer</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1191B785-2044-4A4E-ADA0-BBDE40AE452B</gtr:id><gtr:title>Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb5e167f9c4f242f6847ebad194f200e"><gtr:id>fb5e167f9c4f242f6847ebad194f200e</gtr:id><gtr:otherNames>Schmid D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>545a37abeb4df1.33627073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>160B4828-4B6E-44C4-A44B-6AF249306C45</gtr:id><gtr:title>Enhanced antitumor activity of the photosensitizer meso-Tetra(N-methyl-4-pyridyl) porphine tetra tosylate through encapsulation in antibody-targeted chitosan/alginate nanoparticles.</gtr:title><gtr:parentPublicationTitle>Biomacromolecules</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2612e56ea3356bd6df87a6371ac977cd"><gtr:id>2612e56ea3356bd6df87a6371ac977cd</gtr:id><gtr:otherNames>Abdelghany SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-7797</gtr:issn><gtr:outcomeId>pm_15134_24_23327610</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001805</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>